Upfront investment in strengthening the staffing structure
First written in FY2016. 8 of 26 entries say "Advanced", first in FY2018-Q1. Latest entry: 2026-08-12.
0 other companies' latest entry also says "Mitigated".
- 2026-08-12MitigatedEarnings
「As a result of activities to pass higher purchase prices through to selling prices, continued negotiations to raise management fees in response to inflation, and steady growth in contracts for Medilia®, our Group’s proprietary system supporting medical equipment management at small and medium-sized medical institutions, sales were ¥6,096 million, up 6.6% year on year.」
In the SPD Business, the recovery in earnings became evident through price pass-through, management-fee revisions and an increase in Medilia contracts, following a period involving lost orders and delayed implementations. - FY2026-H1RestatedAnnual report
「Selling and administrative expenses exceeded the previous year's level due to investments in human capital, including salary increases and additional staffing to strengthen the organizational structure, as well as system investments to promote OLBA-DX.」
The company continues salary increases, additional staffing and system investments for OLBA-DX. - FY2025-H1RestatedAnnual report
「Meanwhile, selling, general and administrative expenses exceeded the previous year due to salary base increases as investment in human capital, additional staff to strengthen the organisational structure, and system investment to promote OLBA-DX. However, as a result of efforts to secure profit through procurement improvements and operational efficiency, operating profit came to ¥715 million, up 6.9% year on year.」
While continuing salary increases, additional staffing and system investments for OLBA-DX, the company increased operating profit in the medical equipment business by 6.9% year on year through procurement improvements and operational efficiency gains. - FY2024AdvancedAnnual report
「Meanwhile, selling, general and administrative expenses increased from the previous year due to salary base increases as investment in human capital, additional personnel to strengthen the organisational structure, and proactive system investment to promote OLBA-DX. Strong performance resulted in operating profit of ¥2,037 million, up 7.4% from the previous fiscal year.」
Although selling and administrative expenses increased due to salary increases, additional staffing and system investments for OLBA-DX, operating profit in the medical equipment business increased 7.4% from the previous fiscal year. - FY2024-Q3RestatedAnnual report
「Meanwhile, selling, general and administrative expenses increased from the previous year's level due to salary increases as an investment in human capital, additional staffing to strengthen the organizational structure, system investments to promote OLBA-DX and other factors. However, supported by strong performance, operating profit was ¥1.551 billion, up 12.6% year on year.」
Although salary increases, additional staffing and system investments for OLBA-DX pushed selling, general and administrative expenses above the previous year's level, operating profit in the medical equipment business increased 12.6% year on year. The company discloses strong performance while continuing its human capital and DX investments. - FY2024-Q2RestatedAnnual report
「Meanwhile, selling, general and administrative expenses exceeded the previous year's level due to salary increases as an investment in human capital, additional staffing to strengthen the organizational structure, system investments to promote OLBA-DX and other factors. Operating profit was ¥668 million, down 9.0% year on year.」
Selling and administrative expenses exceeded the previous year's level due to salary increases, additional staffing and system investments for OLBA-DX. The company continues to disclose the increase in costs associated with human capital and DX investments and their impact on profit. - FY2024-Q1Higher selling, general and administrative expenses due to investments in human capital and DXAnnual report
「Meanwhile, selling, general and administrative expenses exceeded the previous year's level due to salary increases as an investment in human capital, additional staffing to strengthen the organizational structure, system investments to promote OLBA-DX and other factors. Operating profit was ¥211 million, down 39.2% year on year.」
While the company implemented salary increases, additional staffing and system investments for OLBA-DX, selling, general and administrative expenses exceeded the previous year's level, and operating profit in the medical equipment business fell 39.2% year on year. - FY2023Higher selling, general and administrative expenses due to increased staffing, investment in system development and higher fuel costsAnnual report
「Meanwhile, selling, general and administrative expenses, hereafter referred to as selling and administrative expenses, exceeded the previous year's level due to increased staffing, investment in system development, higher fuel costs and other factors. Operating profit was ¥1.897 billion, up 0.4% from the previous fiscal year.」
Selling and administrative expenses exceeded the previous year's level due to increased staffing, investment in system development and higher fuel costs. Operating profit in the medical equipment business increased only 0.4% from the previous fiscal year. - FY2023-Q3Higher selling, general and administrative expenses due to increased staffing and investment in system developmentAnnual report
「Meanwhile, selling, general and administrative expenses exceeded the previous year due to staff increases, system development investment, and soaring fuel prices, resulting in operating profit of ¥1.377 billion, down 10.1% year on year.」
In the medical equipment business, selling, general and administrative expenses exceeded the previous year's level due to increased staffing, investment in system development, higher fuel costs and other factors, while operating profit fell 10.1% year on year. - FY2023-Q2AdvancedAnnual report
「As a result, revenue in the medical equipment business was ¥50.694 billion, up 1.0% year on year, and because this exceeded the increase in selling, general and administrative expenses, operating profit was ¥735 million, up 2.1%.」
In the medical equipment business, revenue growth exceeded the increase in selling, general and administrative expenses, resulting in a 2.1% year-on-year increase in operating profit. The disclosure quantifies progress in improving operational efficiency and profitability. - FY2023-Q1AdvancedAnnual report
「As a result, revenue in the medical equipment business was ¥24.844 billion, up 5.2% year on year, and because this exceeded the increase in selling, general and administrative expenses by a wide margin, operating profit was ¥347 million, up 50.3%.」
In the medical equipment business, revenue growth exceeded the increase in selling, general and administrative expenses, resulting in a 50.3% year-on-year increase in operating profit. - FY2022-Q3Personnel expenses continued to increase due to changes to the compensation systemAnnual report
「Meanwhile, operating profit came to ¥117 million, down 2.1% year on year, due mainly to higher personnel costs associated with changes to the salary system.」
Higher personnel expenses resulting from changes to the compensation system continue to weigh on profit in the SPD business. - FY2022-Q2Personnel expenses continued to increase due to changes to the compensation systemAnnual report
「Meanwhile, operating profit was ¥61 million, down 17.2% year on year, due in part to higher personnel expenses resulting from changes to the compensation system.」
Higher personnel expenses resulting from changes to the compensation system again emerged as a factor reducing operating profit in the second quarter, with operating profit in the SPD business down 17.2% year on year. - FY2022-Q1Increase in personnel expenses due to changes to the compensation systemAnnual report
「Operating profit came to ¥27 million, down 27.1% year on year, due mainly to higher personnel costs associated with changes to the salary system.」
In the SPD business, higher personnel expenses resulting from changes to the compensation system were identified as a factor reducing operating profit, adding a cost-increase factor to the trend of efficiency and profitability improvements. - FY2021AdvancedAnnual report
「In addition, the shift of business trips, meetings and training sessions online, undertaken as part of the response to COVID-19, helped restrain selling, general and administrative expenses and improved productivity.」
The company states that moving business trips, meetings and training sessions online helped contain selling, general and administrative expenses and improve productivity. - FY2021-Q3AdvancedAnnual report
「As the company continued to review its inventory management service fees and improve procurement of consumables, operating profit was ¥120 million, up 73.6% year on year.」
As part of its efforts to improve operational efficiency and profitability, the SPD business continued to review inventory management service fees and improve procurement of consumables, resulting in a 73.6% year-on-year increase in operating profit. - FY2020RestatedAnnual report
「Streamlining and improving the efficiency of internal operations through the introduction of RPA (Robotic Process Automation: technology for automating routine tasks) and QC activities (activities to improve operational quality)」
In addition to optimizing staff allocation and streamlining operations, the company identifies the introduction of RPA and QC activities as means of streamlining and improving the efficiency of internal operations. - FY2020-Q1RestatedAnnual report
「In the medical equipment business, we are also continuing to promote productivity improvements through operational streamlining, optimal allocation of resources and other measures.」
The company continues to improve productivity through operational streamlining and optimal allocation of resources. - FY2019ReframedAnnual report
「At the same time, we will improve productivity by streamlining operations through optimal staff allocation, system implementation and other measures.」
The focus has broadened from the previous description of upfront investment to strengthen staffing to improving productivity through optimal staff allocation, system implementation and operational streamlining. - FY2019-Q3Costs increased due to additional staff to strengthen the sales organizationAnnual report
「Meanwhile, as expenses increased due to additional staff and other measures to strengthen the sales organization, revenue was ¥1.569 billion, up 4.3% year on year, while operating profit was ¥65 million, down 4.9%.」
In the care products business, additional staff were hired to strengthen the sales organization, increasing revenue, while higher expenses reduced operating profit. - FY2018AdvancedAnnual report
「Specifically, since the year before last, we have worked to improve productivity and strengthen sales capabilities by reviewing our organizational structure and business activities. These efforts enabled consumables sales, a growth driver, to remain solid at 104.9% of the previous year's level despite the challenging market environment created by efforts to contain medical spending. We also contained the increase in selling, general and administrative expenses to 99.4% of the previous year's level.」
The company continued to review its organizational structure and business activities, disclosing increased consumables sales and containment of selling, general and administrative expenses at 99.4% of the previous fiscal year's level. - FY2018-Q3RestatedAnnual report
「In addition to the activities described above, we worked to improve operating efficiency through changes to the organizational structure and other measures.」
The company continues to pursue improvements in operational efficiency through changes to its organizational structure and other measures, but this disclosure itself contains no new quantitative results. - FY2018-Q2AdvancedAnnual report
「In addition to the activities described above, efforts to improve operating efficiency through changes to the organizational structure and other measures resulted in revenue of ¥48.589 billion, up 2.2% year on year, and operating profit of ¥744 million, up 25.5%, in the medical equipment business.」
The company continued to improve operational efficiency through changes to its organizational structure and other measures, resulting in a 25.5% year-on-year increase in operating profit in the medical equipment business. Meanwhile, costs to secure personnel increased in the SPD business. - FY2018-Q1AdvancedAnnual report
「As a result of efforts to improve operating efficiency through changes to the organizational structure and other measures, the medical equipment business recorded revenue of ¥23.3 billion, up 2.4% year on year, and operating profit of ¥293 million, up 405.2%.」
As the focus shifted from strengthening staffing to improving operational efficiency, the company changed its organizational structure and stated that this led to improved profit in the medical equipment business. - FY2017ReframedAnnual report
「At the same time, the company began reforming its work processes and contained the year-on-year increase in selling, general and administrative expenses to 102% through measures including optimal staff allocation.」
In addition to the previous explanation that the company was making upfront investments to strengthen staffing, the focus has shifted to work-process reform, optimal staff allocation, system implementation, productivity improvement and work-style reform. - FY2016First statedAnnual report
「Meanwhile, selling, general and administrative expenses increased due to upfront investment to strengthen staffing.」
As staffing was expanded, personnel expenses and other selling, general and administrative expenses increased. The consolidated workforce was 1,203 people.